Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Non-metastatic, Hormone naïve Prostate Cancer 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Adenocarcinoma of the Prostate 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × Androgen Antagonists × Clear all
NCT03644303 2026-05-14

TRAP

Royal Marsden NHS Foundation Trust

Phase NA Completed
86 enrolled 27 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00079001 2020-05-12

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Alliance for Clinical Trials in Oncology

Phase 3 Completed
645 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡